

## CORPORATE NEWS

### **Deutsche Biotech Innovativ AG: Significant strengthening of the patent protection for the sepsis drug candidate Adrecizumab**

Hennigsdorf, 21 July 2015 – Deutsche Biotech Innovativ AG ("DBI") has significantly strengthened the patent protection for its main drug candidate Adrecizumab. The biotechnology company based near Berlin has received the notice of allowance from the United States Patent and Trademark Office (USPTO) for the key patent, which provides comprehensive protection in the treatment of sepsis, shock and systemic inflammatory response syndrome (SIRS) by the drug candidate Adrecizumab.

Following the granting of essential patents for Adrecizumab within the European Union in 2014, the DBI's business is now comprehensively protected in the most important markets until the year 2032 at the very least. DBI has therefore reached another strategically important milestone on the path towards strengthening its market position in the area of sepsis treatment.

"The notice of allowance in relation to the US patent is a key component of our strategic patent portfolio and ensures effective market protection for our first-in-class agent for the treatment of sepsis," commented DBI board member Dr. Bernd Wegener.

#### **About Adrecizumab**

Adrecizumab is a humanised antibody and the first therapeutic agent which stabilises the entire body in the case of severe sepsis, since it does not completely block the bioactivity of the body's own peptide hormone Adrenomedullin (ADM), but balances it to a beneficial level. Adrecizumab is designed for the causal and safe treatment of sepsis patients. Following the highly successful process and the promising results of the preclinical studies of safety and efficacy, DBI is currently preparing for the clinical phase I study, expected to start at the end of 2015.

#### **About Deutsche Biotech Innovativ AG**

Deutsche Biotech Innovativ AG ("DBI") is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapeutic solutions for serious illnesses for which no adequate medical solutions have yet been found. The focus of the R&D is on drugs for sepsis and cancer. The company's main product is the patented drug Adrecizumab for decreasing mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a phase I study starting in 2015.

DBI aims to further expand its drug pipeline and invests in the research and development of drugs that possess a high unique selling point potential.

The members of the DBI Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have long-standing experience in the biotechnology field. Both were part of the founders' and management team of B.R.A.H.M.S. AG, a very successful biotechnology company specializing in the development of blood biomarkers for diagnosis and therapy monitoring of serious diseases, which was sold in 2009 for around EUR 330 million. Dr. Bernd Wegener is a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).

**For further information please contact:**

Deutsche Biotech Innovativ AG  
Susanne Wallace  
Tel.: +49 (0)3302 20 77 811  
E-mail: [s.wallace@dbi-ag.de](mailto:s.wallace@dbi-ag.de)

Kirchhoff Consult AG  
Anja Ben Lekhal  
Tel.: +49 (0)40 609 186 55  
E-mail: [anja.benlekhal@kirchhoff.de](mailto:anja.benlekhal@kirchhoff.de)

published:

<http://www.dgap.de/dgap/News/corporate/deutsche-biotech-innovativ-wichtige-staerkung-des-patentschutzes-fuer-sepsiswirkstoff-adrecizumab/?newsID=888341&companyID=363635>